Liaoning He Eye Hospital Group Co., Ltd. Class A

Liaoning He Eye Hospital Group Co., Ltd. Class A

SSZSE:301103
15.35
CNY
-0.29
(-1.85%)
0.17EPS
98.90P/E
2.69BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.22
5.22
6.33
7.08
8.13
6.45
7.5
6.93
6.91
7.19
Basic EPS, GAAP
0.41
0.48
0.68
0.85
0.73
0.22
0.4
-0.17
0.17
0.17
Free Cash Flow per Basic Share
-0.04
0.12
0.08
0.65
1.2
0.67
-0.07
0.25
0.78
- -
Dividend per Share
- -
- -
- -
- -
- -
0.49
1
0.59
0.15
- -
Book Value per Share
5.9
6.39
7.28
8.14
8.87
13.76
13.13
11.9
11.92
12.19
Tangible Book Value per Share
5.79
6.31
7.13
7.95
8.6
13.52
12.91
11.68
11.71
12
Basic Weighted Avg Shares
113
118
118
118
118
148
158
158
158
156
Sales/Revenue/Turnover
476
614
746
838
962
955
1,185
1,096
1,093
1,122
Operating Margin (%)
11.63
14.6
14.3
16.9
14.09
6.66
7.45
-0.1
4.61
4.53
Depreciation Expense
24
28
33
40
99
105
111
112
103
- -
Net Income, GAAP
46
56
81
100
86
33
64
-27
27
27
Effective Tax Rate (%)
36.08
37.37
35.23
32.45
36.64
55.13
45.16
2,267.94
52.88
50.95
Profit Margin (%)
9.66
9.14
10.81
11.95
8.97
3.41
5.36
-2.5
2.5
2.39
Working Capital
479
530
574
569
669
1,816
1,584
1,236
1,309
1,360
LT Debt
- -
- -
- -
196
188
241
209
173
130
124
Total Equity
690
747
862
963
1,050
2,176
2,072
1,880
1,884
1,927
Return on Invested Capital (%)
- -
7.8
9.96
9.26
6.53
1.7
2.42
-5.99
1.32
1.34
Return on Capital (%)
- -
7.8
10.33
9.84
8.16
2.06
3.2
-11.97
1.56
1.47
Return on Common Equity (%)
- -
7.81
10.02
10.98
8.58
2.02
2.99
-1.39
1.45
1.4

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
37
37
38
LT Borrowings
- -
- -
- -
LT Finance Leases
132
129
124
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
158
158
158
Market Capitalization
3,105
2,367
2,691

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,495
1,482
1,546
Cash, Cash Equivalents & STI
1,353
1,342
1,404
Accounts Receivable, Net
37
31
35
Inventories
75
80
77
Total Current Liabilities
175
158
185
Payables & Accruals
- -
- -
- -
ST Debt
37
37
38
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
20.5%
0.24%
Free Cash Flow
- -
-55.63%
213.33%
Net Income, GAAP
- -
-64.8%
-199.77%
Sales/Revenue/Turnover
- -
6.06%
-0.28%
Total Cash Common Dividend
- -
- -
-75.21%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
285
300
280
231
1,096
2025
291
269
- -
237
1,093
2026
305
280
299
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
-0.03
-0.05
-0.28
-0.17
2025
0.21
0.08
- -
-0.17
0.17
2026
0.21
0.06
0.08
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.59
2025
- -
- -
- -
- -
0.15
2026
- -
- -
- -
- -
- -

Company Description

CEO
Xingru He
Full Time Employees
3,174
Sector
Health services
Industry
Hospital/Nursing management
Address
Shenyang China
IPO Date
Mar 22, 2022
Business
Liaoning He Eye Hospital Group Co., Ltd. is a China-based medical services enterprise that provides comprehensive ophthalmic and optometry healthcare services, ophthalmic medical device distribution, and digital eye health management solutions. Founded in 1995 and headquartered in Shenyang, Liaoning Province, the company operates an integrated healthcare network structured around a three-tier eye care delivery system that connects regional tertiary eye hospitals with local specialty clinics and community vision centers. The company organizes its business operations primarily into two core segments: Medical Services and Optometry Services. Its clinical healthcare portfolio encompasses refractive surgical procedures, including laser-assisted in situ keratomileusis (LASIK), full-femtosecond laser surgery, and implantable collamer lens (ICL) implantation; cataract surgical treatments, comprising standard phacoemulsification, refractive cataract surgery, and premium multifocal and toric intraocular lens (IOL) implantations; complex ocular disease treatments, which cover vitreoretinal disease management, surgical and medical therapies for glaucoma, diabetic retinopathy interventions, corneal and external eye disease treatments, strabismus and amblyopia correction, ocular trauma surgery, orbital disease care, and integrated Traditional Chinese Medicine (TCM) ophthalmic therapies; and specialized dry eye disease management, offering pulsed light therapies, meibomian gland physical treatments, and customized ocular surface regimens. Within its optometry division, the company provides adolescent myopia prevention and control services; comprehensive vision examination and refractive testing; prescription spectacles and optical frames; specialized orthokeratology (OK) contact lenses; proprietary functional lenses under the Zhaoxi and Zhaoyue product lines; custom soft and rigid gas-permeable contact lenses; visual function rehabilitation training; and the wholesale and retail distribution of ophthalmic consumables, optical diagnostic instruments, and related healthcare products. Geographically, Liaoning He Eye Hospital Group maintains a strong market presence in Northeast China while systematically expanding its hospital and vision center network across key economic clusters, including the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing metropolitan area. In recent developments, the company has accelerated its asset-light expansion by introducing a specialized franchise model alongside direct-operated optometry clinics to broaden nationwide grassroots coverage. The group has advanced its digital transformation and artificial intelligence initiatives under its Smart City of Light strategy, integrating big data, AI-assisted diagnostic screening tools, and telemedicine platforms to facilitate whole-lifecycle ocular health management. On the research front, the company was approved to lead a national key research and development project focused on proactive healthcare and aging management, developing intelligent biometric health identification systems based on ocular and facial features. Additionally, the group earned international recognition as an accredited ophthalmic physician training institution from the International Ophthalmology Foundation (OF), progressed cross-border overseas acquisition initiatives, and executed corporate share repurchase programs to support long-term equity incentive frameworks.